SCHEMBL17521920

SCHEMBL17521920

NCCOCCOC1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](OC(N)=O)[C@H](O)[C@@H]1O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 3/20 0.60
LGALS3 P17931 5/20 0.46
LGALS8 O00214 3/20 0.46
LGALS4 P56470 3/20 0.46
CXCL10 P02778 1/20 0.43
CXCL8 P10145 1/20 0.43
CCL2 P13500 1/20 0.43
CCL5 P13501 1/20 0.43
CXCL12 P48061 1/20 0.43
CD209 Q9NNX6 2/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GJA1 P17302 1/20 0.38
GJB2 P29033 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16126199 0.93 IGF2R (0.57) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL17521929 0.93 IGF2R (0.57) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL17521939 0.93 IGF2R (0.57) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL17521900 0.93 IGF2R (0.56) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL16126954 0.88 IGF2R (0.67) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL17521919 0.87 IGF2R (0.56) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL21083292 0.87 IGF2R (0.65) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL21083270 0.87 IGF2R (0.65) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL16126762 0.83 IGF2R (0.44) IGF2RLGALS3LGALS8LGALS4CXCL10
SCHEMBL17521951 0.83 IGF2R (0.44) IGF2RLGALS3LGALS8LGALS4CXCL10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9919055-B2 Sugar-linker-drug conjugates ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-20 US disclosed
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-18 US disclosed
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES FUT5, FUT6, B3GNT2 IGF2R 1906/4885LGALS3 790/4885LGALS8 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.